Results for "antiviral"
ViiV Healthcare announces CHMP Positive Opinion for Dovato® (dolutegravir/lamivudine) as a once-daily, single-pill, two-drug regimen for the treatment of HIV infection
First published: 26 April 2019
Recommendation based on landmark GEMINI 1 & 2 studies which demonstrated non-inferior efficacy of dolutegravir + lamivudine compared to a traditional dolutegravir-based, three-drug regimen, in HIV-...
ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019
First published: 22 July 2019
Week 96 data from the BRIGHTE study of first-in-class fostemsavir continue to show improvement in virologic suppression and immunologic response
ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available
First published: 02 July 2020
ViiV today announced that the US FDA has approved Rukobia (fostemsavir), 600 mg extended-release tablets.
ViiV Healthcare announces FDA approval to lower the weight limit for dolutegravir in children and adolescents living with HIV
First published: 10 June 2016
The US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for dolutegravir 10mg and 25mg oral tablets.
Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
First published: 17 December 2020
Global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalised adults with COVID-19
ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen
First published: 18 November 2016
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders
ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection
First published: 03 July 2019
Authorisation based on GEMINI pivotal trials in which Dovato achieved non-inferior efficacy compared to a dolutegravir-based, three-drug regimen through 48 weeks, with no cases of resistance.
ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance
First published: 24 July 2019
ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent ...
ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV
First published: 18 July 2016
ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy for Triumeq® (dolutegravir/abacavir/lamivudine) c...
New Phase IIIb/IV data show switching to once-daily Triumeq® maintains HIV viral suppression
First published: 23 September 2015
ViiV Healthcare today announced 24-week data from the Phase IIIb/IV STRIIVING study